A N-methylated antimicrobial peptide targets the fructose transporter FruA of Staphylococcus aureus.

Authors

Qi Liu, Yaxuan Li, Zhichen Jiang, Shen Fan, Wei Ding, Weipeng Zhang

Published in

The Journal of antibiotics. Jul 24, 2026. Epub Jul 24, 2026.

Abstract

Antimicrobial peptides (AMPs) represent promising alternatives to conventional antibiotics, but their therapeutic application is often hindered by suboptimal stability and poorly defined mechanisms of action. To overcome these limitations, we engineered a peptide named CAMP502NC3 through chemical modification of its parent peptide, CAMP502, which originates from marine biofilm microorganisms. The design included N-terminal acetylation, C-terminal amidation, and N-methylation of the lysine at position 3 to improve stability. CAMP502NC3 demonstrated potent activity against Staphylococcus aureus and remained stable under diverse conditions, including varying pH, high salinity, and protease exposure. Mechanistically, CAMP502NC3 leads to bacterial membrane depolarization. Transcriptomic and biochemical analyses further revealed that it interferes with key metabolic pathways, notably the fructose-specific phosphotransferase system. Molecular docking indicated direct binding of CAMP502NC3 to the fructose transporter FruA. This study illustrates how rational peptide engineering can generate stable and potent AMPs with precise membrane-associated targets, as exemplified by CAMP502NC3.

PMID:
42498784
Bibliographic data and abstract were imported from PubMed on 25 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.